Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group ACYW135 meningococcal conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigational quadrivalent conjugate vaccine developed by Sinovac Biotech for the prevention of epidemic meningitis (invasive meningococcal disease) caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine utilizes capsular polysaccharides from these four serogroups, each chemically conjugated to a carrier protein. This conjugation process is designed to convert the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby enhancing immunogenicity, particularly in infants and young children, and promoting the development of long-term immunological memory. It is currently being evaluated in Phase 3 clinical trials to compare its safety and immunogenicity against licensed active comparators in the pediatric population.
- Other names
- ACYW135 meningococcal conjugate vaccineACYW-135 meningococcal conjugate vaccineACYW 135 meningococcal conjugate vaccineQuadrivalent meningococcal conjugate vaccineSinovac ACYW135 meningococcal conjugate vaccineMCV4MCV-4MCV 4
02
Targets
Neisseria meningitidis capsular polysaccharide
Beyond the preview
Go deeper on Group ACYW135 meningococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group ACYW135 meningococcal conjugate vaccine.